Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Cytrx Cp (CYTR) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 48,560
  • Shares Outstanding, K 95,150
  • Annual Sales, $ 100 K
  • Annual Income, $ -58,590 K
  • 36-Month Beta 1.39
  • Price/Sales 468.43
  • Price/Book 1.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.99
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.25 on 03/07/08
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.41 +26.83%
on 11/04/16
0.74 -29.73%
on 11/29/16
+0.09 (+20.93%)
since 11/02/16
3-Month
0.41 +26.83%
on 11/04/16
0.74 -29.73%
on 11/29/16
-0.05 (-8.77%)
since 09/02/16
52-Week
0.41 +26.83%
on 11/04/16
3.66 -85.79%
on 04/25/16
-2.61 (-83.39%)
since 12/02/15

Most Recent Stories

More News
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the appointment of Earl Warren Brien, M.D., a noted sarcoma surgeon, industry...

CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR) today announced positive updated results from its pivotal Phase 3 clinical trial evaluating aldoxorubicin compared to investigator's choice in patients with relapsed or...

CytRx Reports Third Quarter 2016 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2016, and provided...

Research Reports Coverage on Biotech Stocks -- Tesaro, Aralez Pharma, Rexahn Pharma, and CytRx

In today's pre-market research, Stock-Callers.com takes notice of the Biotech industry, which has had a weak performance this year. The iShares NASDAQ Biotechnology Index is lower over 25% year-to-date,...

CytRx Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial at ESMO 2016 Congress

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today presented results from its on-going Phase 1b/2 trial of aldoxorubicin in combination...

DEADLINE TOMORROW ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against CytRx Corporation and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 22, 2016 / Khang & Khang LLP (the "Firm") announces a class action lawsuit was filed against CytRx Corporation ("CytRx" or the "Company") (Nasdaq: CYTR). Investors who...

24-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming September 23rd Deadline in the Class Action Lawsuit Against CytRx Corporation

Law Offices of Howard G. Smith reminds investors of the upcoming September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased...

DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against CytRx Corporation and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 22, 2016 / Lundin Law PC (the "Firm") announces that a class action was filed against CytRx Corporation ("CytRx" or the "Company") (Nasdaq: CYTR) concerning possible...

DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of CytRx Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 23, 2016 - CYTR

The following statement is being issued by Levi & Korsinsky, LLP:

2-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against CytRx Corporation and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 21, 2016 / Khang & Khang LLP (the "Firm") announces a class action lawsuit was filed against CytRx Corporation ("CytRx" or the "Company") (Nasdaq: CYTR). Investors who...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

See More

Support & Resistance

2nd Resistance Point 0.56
1st Resistance Point 0.54
Last Price 0.52
1st Support Level 0.49
2nd Support Level 0.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.